Biogen
Top Ten most popular articles on Pharmafile.com this week
March 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Biogen, Celgene, EMA, Gilead, HIV, Herceptin, Japan, NHS, Ontruzant, Sanofi, opioid crisis, opioids, pharma, real world data, top ten, zinbryta
After a particularly jarring bout of cold weather and snow, we may just have seen off the worst of winter …
Abbvie and Biogen pull MS drug Zinbryta following urgent EMA safety review
March 5, 2018Sales and Marketing AQbbvie, Biogen, EMA, Europe, mulyiple sclerosis, pharma, zinbryta
Biogen and Abbvie have announced their intention to voluntarily withdraw their multiple sclerosis therapy Zinbryta (daclizumab) from all global markets …
Biogen shares hit by key Alzheimer’s drug concerns
February 15, 2018Research and Development Alzheimer's, Biogen, MSD, Merck, biotech, drugs, pharma, pharmaceutical
Biogen made investors very nervous after it announced that it was choosing to add an additional 510 patients to its …
Biogen halts Tysabri trial after failure in acute ischemic stroke
February 8, 2018Research and Development Biogen, Tysabri, multiple sclerosis, pharma, stroke, trial failure
Biogen has halted its investigation into the efficacy of its humanised monoclonal antibody Tysabri (natalizumab) in the treatment of acute …
Biogen announces acquisition along with financials, but it’s tiny
January 26, 2018Medical Communications, Sales and Marketing Biogen, Karyopharm, biotech, drugs, pharma, pharmaceutical
Biogen is one those companies, like Sanofi until its recent Bioverativ acquisition, that has real pressure to make a big …
Biogen’s Spinraza to go before NICE
January 22, 2018Sales and Marketing Biogen, Spinraza, biotech, drugs, pharma, pharmaceutical
Biogen received marketing approval from the European Commission for Spinraza (nusinersen), its treatment for spinal muscular atrophy (SMA), in May …
Eisai and Biogen Alzheimer’s drug stumbles at P2
December 21, 2017Medical Communications, Research and Development Biogen, Eisai, biotech, drugs, pharma, pharmaceutical
Only a few months ago, it was announced that Eisai had decided to opt into the development process of BAN2401. …
Samsung completes hat-trick of big biosimilar approvals
August 25, 2017Medical Communications, Sales and Marketing Biogen, Samsung Bioepis, biosimilars, biotech, drugs, pharma, pharmaceutical
Samsung Bioepis has announced that it, alongside its partner Biogen, has secured European Commission approval for its biosimilar version of …
Biogen steal away Pfizer VP to boost R&D plans
August 1, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, Pfizer, biotech, drugs, pharma, pharmaceutical
Pfizer has had a tough time keeping hold of its Vice President’s involved in R&D of late, losing high-profile researcher, …
New data shows pharma has not cut back on controversial payments to physicians
July 6, 2017Medical Communications, Sales and Marketing Allergan, Biogen, Celgene, Sanofi, Valeant
Despite increasing controversy arising over the years due to the questionable relationship between physicians and pharma and the money which …
Biogen appoint new Head of Global Therapeutic Operations
June 27, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, Jean-Paul Kress
Biogen announced that Jean-Paul Kress has been appointed to the position of Executive Vice President and President, International, and Head …
Alexion secures ex-Biogen Chief Financial Officer
June 14, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alexion, Biogen, appointment
Alexion Pharmaceuticals has announced that it has snatched up Biogen’s long-serving Chief Financial Officer Paul Clancy and will instate him …
Collegium bring in former Biogen SVP as new COO
May 31, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, Collegium pharmaceutical
Collegium Pharmaceutical has announced the appointment of Joseph Ciaffoni to the position of Executive Vice President and Chief Operating Officer. …
EMA gives positive opinion on Biogen’s spinal muscular atrophy drug Spinraza
April 25, 2017Manufacturing and Production, Sales and Marketing Biogen, Ionis, Spinraza, spinal muscular atrophy
Biogen has revealed that Spinraza (nusinersen), its treatment for spinal muscular atrophy (SMA) , has received a positive opinion from …
First treatment for form of MS approved by FDA
March 30, 2017Sales and Marketing Biogen, Genentech, MS, Roche
In big news for sufferers of MS and the company that developed the drug, Roche subsidiary Genetech, the FDA has …
